Oncodistinct trials (REGINA, AVERECTAL & SHAPERS) at ESMO GI 2024
➥ REGINA : A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN stage II-III rectAl cancer
📣 Francesco Sclafani presented REGINA trial at ESMO GI 2024 in Munich, Germany. Francesco Sclafani shared insights about Neoadjuvant regorafenib, nivolumab and short-course radiotherapy for stage II-III. Please do not hesitate to watch this presentation with the link below
🔗 https://ow.ly/ttA750SI5TvÂ
Â
➥ AVERECTAL study : SO-30 Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma
📣 Presentation of our final results of Averectal study with a poster, Oncodistinct 005 study, using chemoimmunotherapy after short course radiation therapy in MSS locally advanced rectal cancer
📣 The SHAPERS trial design led by Francesco Sclafani has been published in the ESMO Gastrointestinal Oncology Volume 4, June 2024 edition! 🎉
The paper is available here:
🔗 https://lnkd.in/eyb_sY8r
